摘要
目的观察抗骨髓炎片(KST)对家兔慢性骨髓炎(CO)的改善作用。方法将金黄色葡萄球菌注入家兔右胫骨骨髓腔内建立CO模型,将CO家兔分为模型组、庆大霉素(60 mg/kg)组及KST高、低剂量(480、240 mg/kg)组,另设假手术组,ig给药。术后第2、4、6周对右胫骨行X-线检查并做诊断分型,采血进行白细胞计数,取血清检测C-反应蛋白(CRP)含量,术后第6周取右胫骨检测核因子κB(NF-κB)的阳性表达。结果 KST高、低剂量组术后第2、4、6周的X-片诊断分型与模型组比较均显著改善,有统计学意义(P<0.05、0.01);与模型组比较,KST高、低剂量组的白细胞计数、血清CRP含量、胫骨组织NF-κB表达在第2、4、6周均显著降低(P<0.05、0.01)。结论 KST对CO家兔具有保护作用,其机制可能与抑制致病菌、缓解炎症反应、下调炎性反应调控因子NF-κB等环节有关。
Objective To observe the protective effect of Kanggusuiyan Tablet(KST) against rabbits with chronic osteomyelitis(CO). Methods CO model of rabbit was achieved by intra-shinbone marrow injection of Staphylococcus aureus. CO rabbits were divided randomly into five groups, including sham group, model group, KST high and low dose(480 and 240 mg/kg, respectively)group and gentamicin(60 mg/kg) group. Drugs were administered orally daily for six weeks. The X-ray of right shinbone in rabbits were evaluated and graded, leucocyte count and level of C-reactive protein(CRP) in serum were examined on the 2nd, 4th and 6th week post-injection, respectively. At the end of the experiment, all the rabbits were sacrificed and the expression of NF-κB in right shinbone was determined by immunohistochemistry. Results The grading of X-ray in KST groups(480 and 240 mg/kg) were significantly improved compared with that of model group on the 2nd, 4th and 6th week, respectively(P < 0.05 or P < 0.01).Comparing to those of model group, leucocyte count and sera CRP levels in KST groups were significantly reduced on the 2nd, 4th and 6th week, respectively(P < 0.01). KST(480 and 240 mg/kg) significantly decreased the expression of NF-κB in shinbone compared with that of model group(P < 0.01). Conclusion The protective effect of KST against CO seems to be associated with inhibition of pathogenic bacteria, improvement of inflammation and downregulation of NF-κB, etc.
作者
邢玉琪
李冬梅
张国斌
XING Yuqi;LI Dongmei;ZHANG Guobin(Department of Pharmacy, Tsinghua University Yuquan Hospital, Beijing 100040;Pharmacy, Beijing Intech Jingxi Rehabilitation Hospital, Beijing 100043;Pharmacy College, Hc'nan University of Traditional Chinese Medicine, Zhengzhou 450046, China)
出处
《药物评价研究》
CAS
2019年第6期1115-1119,共5页
Drug Evaluation Research